Health Technology Nichi-Iko Pharmaceutical Co., Ltd. Business Summary
Nichi-Iko Pharmaceutical Co., Ltd. engages in the manufacturing, sales, distribution, export, import and related activities for various types of pharmaceutical products. The company provides its products to medical institutions such as hospitals, medical clinics and dispensing pharmacies. Its medical products are divided into ethical pharmaceutical products which are formulated according to a prescription issued by a doctor in a hospitals or clinics, as well as general pharmaceutical products which can be purchased at pharmacies and drugstores without a prescription needed. It also provides treatments for circulatory, digestive, respiratory, central and peripheral nervous systems and others. The company was founded on July 15, 1965 and is headquartered in Toyama, Japan.
Financial Highlights
Mar 2020
JPY USD Revenue 190,076M 1,748.21M Gross Profit 37,320M 343.24M Operating income 7,572M 69.64M Income before tax 7,396M 68.02M Net income 5,133M 47.21M EBITDA 19,443M 178.82M Diluted EPS 80.12 0.73 Dividends Per Share 30 0.27 Total Assets 336,819M 3,119.99M Total liabilities 219,644M 2,034.58M Total equity 115,827M 1,072.91M Operating cash flow 18,450M 169.69M Currency in JPY Currency in USD
Historical Data Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Revenue
143,513M
149,263M
164,717M
166,592M
190,076M
Gross Profit
53,313M
37,611M
40,803M
33,158M
37,320M
Operating income
12,910M
10,026M
13,200M
7,221M
7,572M
Income before tax
15,359M
5,963M
9,067M
8,903M
7,396M
Net income
11,031M
4,796M
8,069M
6,864M
5,133M
EBITDA
24,200M
17,091M
22,179M
16,987M
19,443M
Diluted EPS
184.01
84.08
142.92
114.03
80.12
Dividends Per Share
30
30
30
30
30
Total Assets
161,128M
268,900M
278,364M
306,838M
336,819M
Total liabilities
78,531M
185,725M
190,819M
190,511M
219,644M
Total equity
82,597M
83,171M
87,542M
116,323M
115,827M
Operating cash flow
7,097M
-4,076M
18,925M
23,811M
18,450M
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Revenue
1,195.10M
1,378.39M
1,486.18M
1,502.25M
1,748.21M
Gross Profit
443.96M
347.32M
368.15M
299.00M
343.24M
Operating income
107.50M
92.58M
119.09M
65.11M
69.64M
Income before tax
127.90M
55.06M
81.80M
80.28M
68.02M
Net income
91.86M
44.28M
72.80M
61.89M
47.21M
EBITDA
201.52M
157.82M
200.11M
153.18M
178.82M
Diluted EPS
1.53
0.77
1.28
1.02
0.73
Dividends Per Share
0.24
0.27
0.27
0.27
0.27
Total Assets
1,433.58M
2,413.17M
2,617.43M
2,772.17M
3,119.99M
Total liabilities
698.70M
1,666.74M
1,794.25M
1,721.19M
2,034.58M
Total equity
734.88M
746.39M
823.14M
1,050.93M
1,072.91M
Operating cash flow
59.10M
-37.64M
170.75M
214.71M
169.69M
Valuation Measures
Mar 2020
PER 17.74 ROA 1.59% ROE 4.42% Operating margin 3.98% Profit margin 2.70%
Key executives
President & Representative Director:
Yuichi Tamura
Finance Manager:
Naoyuki Okada
Head-Compliance Management & Guidance:
Yasutomo Sai
Director, VP, Head-CSR, ESG & Business Creation:
Kenji Akane
Executive Officer & Personnel Manager:
Keiichi Arakawa Shareholders
TAMURA YUICHI /NICHI IKO PHARMACEUTICAL/ (12.9%)
Hokuhoku Financial Group, Inc. (4.3%)
Asset Management One Co., Ltd. (3.9%)
Nomura Asset Management Co., Ltd. (2.5%)
The Vanguard Group, Inc. (1.8%)
Sumitomo Mitsui DS Asset Management Co., Ltd. (1.8%)
Dimensional Fund Advisors LP (1.5%)
Nichiiko Pharmaceutical Employee Stock Pwnership Plan (1.5%)
Nipro Corp. (1.4%)
Nichi-Iko Pharmaceutical Co., Ltd. (1.4%)
Related Companies
Nichi-Iko Pharma Tech Co., Ltd.
Elmed Co., Ltd.
Nichi Iko Pharmaceutical Trust
SterRx LLC
Nichi-Iko Pharmaceutical Employee Incentive Plan
Nichiiko Pharma KK
Nichiiko Osaka KK
Yakuhan Pharmaceutical Co., Ltd.
Sagent Pharmaceuticals, Inc.
Kobayashi Pharmaceutical Industries Co. Ltd.
Maruko Pharmaceutical Co. Ltd. /Sale & Marketing Ops./
Oriental Pharmaceutical Co., Ltd.
Teikoku Medix Co., Ltd.
Japan Galen, Inc.
Maruko Pharmaceutical Co. Ltd.
Nichiiko Pharmaceutical Employee Stock Pwnership Plan
Competitors
Dr. Reddy's Laboratories Ltd.
Cumberland Pharmaceuticals Inc.
Five Prime Therapeutics, Inc.
Amphastar Pharmaceuticals Inc
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A
Copyright © 2021 FactSet Research Systems Inc. All rights reserved.
Last Updated on 5 Mar, 2021
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter Find out more
